J&J’s Shockwave Medical Launches Novel Javelin Intravascular Lithotripsy Catheter for Treating Calcified Peripheral Artery Disease

Shockwave Medical (now part of Johnson & Johnson) has launched the Javelin Peripheral Intravascular Lithotripsy (IVL) Catheter in the U.S.
The Javelin is a new non-balloon-based IVL platform designed to modify calcium and cross extremely narrowed vessels in patients with peripheral artery disease (PAD).
It features a single 120-pulse lithotripsy emitter at the distal tip of the 150cm long catheter.
The device is intended to treat calcified lesions in peripheral arteries that are difficult to cross with other devices.
Clinical trials showed a 99% technical success rate and only 1.1% major adverse event rate at 30 days.
It received FDA clearance in late 2024 based on positive clinical trial results.
The Javelin expands Shockwave's IVL portfolio for treating calcified lesions across the peripheral vasculature.